NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 41 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $57,719 | +18.2% | 69,541 | -0.3% | 0.00% | – |
| Q1 2023 | $48,836 | +37.5% | 69,765 | 0.0% | 0.00% | – |
| Q4 2022 | $35,510 | -21.1% | 69,765 | 0.0% | 0.00% | – |
| Q3 2022 | $45,000 | -37.5% | 69,765 | -0.2% | 0.00% | – |
| Q2 2022 | $72,000 | -87.6% | 69,890 | -77.4% | 0.00% | – |
| Q1 2022 | $581,000 | -63.1% | 308,838 | -5.4% | 0.00% | – |
| Q4 2021 | $1,574,000 | -38.1% | 326,497 | -7.1% | 0.00% | – |
| Q3 2021 | $2,541,000 | -24.5% | 351,388 | -3.6% | 0.00% | -100.0% |
| Q2 2021 | $3,364,000 | -26.9% | 364,492 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $4,603,000 | -19.4% | 373,955 | -7.7% | 0.00% | 0.0% |
| Q4 2020 | $5,714,000 | +14.3% | 405,224 | -2.7% | 0.00% | 0.0% |
| Q3 2020 | $4,998,000 | +115.0% | 416,503 | +197.3% | 0.00% | 0.0% |
| Q2 2020 | $2,325,000 | +170.7% | 140,078 | +85.7% | 0.00% | – |
| Q1 2020 | $859,000 | +27.3% | 75,440 | +37.7% | 0.00% | – |
| Q4 2019 | $675,000 | +407.5% | 54,769 | +17.7% | 0.00% | – |
| Q3 2019 | $133,000 | – | 46,535 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
| ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
| EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
| Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
| Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
| Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
| Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
| Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
| PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
| Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |